Wythe Therapeutics

Wythe Therapeutics is an early-stage biotechnology company focused on developing next-generation genetic medicines through advanced viral vector engineering. The company specializes in the design and optimization of novel adeno-associated virus (AAV) capsids to overcome current limitations in gene delivery, such as tissue specificity, immunogenicity, and manufacturing efficiency. By leveraging high-throughput screening and directed evolution, Wythe Therapeutics aims to create highly targeted therapies for a range of genetic disorders, with a primary focus on central nervous system and ocular indications. The company operates out of the Alexandria Center for Life Science in New York City, positioning itself within a major hub for biomedical innovation.